# A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

> **NCT05827926** · PHASE1,PHASE2 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 1758 (actual)

## Conditions studied

- SARS-CoV-2
- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Vaccine 1
- **BIOLOGICAL:** mRNA-1083.1
- **BIOLOGICAL:** mRNA-1083.2
- **BIOLOGICAL:** mRNA-1083.3
- **BIOLOGICAL:** Investigational Influenza Vaccine 1
- **BIOLOGICAL:** Investigational COVID-19 Vaccine 1
- **BIOLOGICAL:** COVID-19 Vaccine 1
- **BIOLOGICAL:** Investigational Influenza Vaccine 2
- **BIOLOGICAL:** Influenza Vaccine 2
- **BIOLOGICAL:** mRNA-1083
- **BIOLOGICAL:** Investigational COVID-19 Vaccine 2
- **BIOLOGICAL:** COVID-19 Vaccine 2

## Key facts

- **NCT ID:** NCT05827926
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-14
- **Primary completion:** 2024-12-03
- **Final completion:** 2024-12-03
- **Target enrollment:** 1758 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827926, "A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05827926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*